Skip to content

Randomized Clincal Trial on the Effect of a Restricted Gluten Contamination Elimination Diet Among Celiacs [GluCED]

Randomized Clincal Trial on the Effect of a Restricted Gluten Contamination Elimination Diet in Achieving Complete Mucosal Healing Among Celiac Patients With Persisting Minimal Duodenal Lesions During Gluten Free Diet [GluCED]

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02711696
Acronym
GluCED
Enrollment
30
Registered
2016-03-17
Start date
2014-03-31
Completion date
2016-01-31
Last updated
2016-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Celiac Disease

Keywords

Celiac Disease,, Gluten Free Diet, Gluten contamination

Brief summary

The study assessed whether compete healing of duodenal mucosa in celiac patients with persistent Marsh I-II lesion after 1 year of gluten free diet (GFD): * could be achieved by adoption of a diet based exclusively on naturally gluten free products, with the elimination of commercially available processed food (GCED, Gluten Contamination Elimination Diet); * may depend upon time of exposure to GFD. Investigators studied two cohorts of celiac patients, both on GFD, for at least one year: * cohort A: patients re-biopsied after three months on GCED; * cohort B: patients re-biopsied after a minimum of further two years on standard GFD.

Detailed description

Despite strict adherence to gluten free diet (GFD), the complete healing of the duodenal mucosa of celiac patients is rarely achieved. The cause of the persistence of the inflammation is not yet understood. It is well known that there is a high degree of variability in individual response to gluten with some patients worsening of duodenal histology upon exposure to very small amount of gluten. This observation suggest that contamination with gluten of commercially available processed food and/or small amount of gluten in processed foods labeled gluten-free (less than 20 ppm) may prevent complete mucosal healing. This explanation is indirectly supported by a study of Hollon et al. (2013) showing that persistence of gastrointestinal symptoms in celiac patients on a GFD is abolished, in 85% of cases, by the adoption of a diet based exclusively on naturally gluten-free products, and on the elimination from the diet of commercially available processed food and products labeled gluten free (Gluten Contamination Elimination Diet, GCED). The main aim of this study was to assess whether the complete healing of duodenal mucosa in patients with persistent Mars I-II lesions after 1 year on GFD i) could be achieved, as a proof of the concept, by the adoption of a GCED OR ii) may depend upon time of exposure to GFD. To achieve this aim investigators studied 2 cohorts of patients with Marsh I-II lesion after 1 year on GFD: cohort A re-byopsied after 3 month GCED , and cohort B re-biopsied after a minimum of further 2 years on standard GFD.

Interventions

BEHAVIORALGCED, Gluten Contamination Elimination Diet

A Gluten Free diet based exclusively on naturally gluten-free products and foods, with the elimination from the diet of all commercially available processed food and products labeled gluten free (Gluten Contamination Elimination Diet, GCED).

Sponsors

Università degli Studi di Brescia
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

* Marsh I-II lesion at 12-18 months after starting GFD * Negative Celiac Disease serology * Strict adherence to gluten free diet without digression

Exclusion criteria

* presence of Gastrointestinal Symtoms * presence of Helicobacter pylori infection

Design outcomes

Primary

MeasureTime frameDescription
Histologic classificationthree months in cohort A, at least sixty months in cohort BAssessment of Marsh class (0-I-II-III) on duodenal biopsies in participants from both cohorts

Secondary

MeasureTime frameDescription
Celiac disease serologythree months in cohort A, at least sixty months in cohort BIgA t-TG (class A Antibodies anti tissue Transglutaminases) were measured in particiapnts serum at the same time of dudenal biopsy \[Eu t-Tg Eurospital, Trieste, Italy\]
TCR+ T cells countthree months in cohort A, sixty months in cohort BTCR+ T cells were identified using a commercially available method suitable for formalin fixed paraffin embedded dudenal biopsies. A mean of the count of TCR+T cells was obtained with a cut-off value of 4 out of 100 epithelial cells.
Eosinophils countthree months in cohort A, sixty months in cohort BEosinophils were identified and counted on duodenal biopsies with a cut off value of 2 out of 100 epithelial cells.

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026